COMP <GO>
ELAN vs JNJ // FREE CASH FLOW YIELD
Elanco Animal Health Incorporated (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ELAN 3
— JNJ 10
▲ FREE CASH FLOW YIELD LEADER: JNJ
LAST: $23.06 (-0.77%) • MKT CAP: $11.61B
fcf-yield
2.45%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELAN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.00% | 67.90% | -12.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 25.50% | -28.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.45% | 2.97% | -0.52 | JNJ | /fcf-yield <GO> |
| Operating Margin | -6.00% | 34.70% | -40.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 28.50% | -33.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.20% | 6.00% | +0.20 | ELAN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.24 | 5.59 | -4.35 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | ELAN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 60.4 | -7.89 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.08 | -0.12 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 23.0x | -3.00 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.61B | $662.49B | -$650.88B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELAN REV | JNJ REV | ELAN GROSS % | JNJ GROSS % | ELAN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.71B | $94.19B | 55.0% | 67.9% | $284.0M | $19.70B |
| FY 2024 | $4.44B | $88.82B | 54.9% | 69.1% | $394.0M | $19.84B |
| FY 2023 | $4.42B | $85.16B | 44.0% | 44.0% | $72.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAN // BETA 0.96
JNJ // BETA 1.08